Mercado Europeu de Medicamentos de Insulina Humana e Dispositivos de Administração – Tendências da Indústria e Previsão para 2028

Análise de Mercado e Insights: Mercado Europeu de Medicamentos para a Insulina Humana e Dispositivos de Administração

Espera-se que o mercado europeu de medicamentos de insulina humana e dispositivos de administração testemunhe um crescimento do mercado a uma taxa de 5,68% no período de previsão de 2021 a 2028. O relatório Data Bridge Market Research sobre o mercado de medicamentos de insulina humana e dispositivos de administração fornece análises e insights sobre os diversos fatores que deverão prevalecer ao longo do período de previsão, ao mesmo tempo que fornecem os seus impactos no crescimento do mercado. O aumento do estilo de vida sedentário está a aumentar o crescimento do mercado de medicamentos e dispositivos de administração de insulina humana.

A insulina é conhecida por ser uma hormona proteica que ajuda a controlar o nível de açúcar no sangue em doentes cujo organismo não consegue produzir insulina suficiente. A insulina diminui o nível de glicose no sangue, aumentando a absorção de glicose nos tecidos adiposos e nos músculos.

Os principais fatores que deverão impulsionar o crescimento do mercado de medicamentos e dispositivos de administração de insulina humana no período de previsão são o aumento da incidência de casos de diabetes tipo 2 em todo o mundo. Além disso, prevê-se que os desenvolvimentos no design de dispositivos de insulina impulsionem ainda mais o crescimento do mercado de medicamentos de insulina humana e dispositivos de administração. Além disso, estima-se que os reembolsos adequados nos sistemas de saúde de todo o mundo amortecem ainda mais o crescimento do mercado de medicamentos e dispositivos de administração de insulina humana. Por outro lado, projeta-se que o aumento do preço relativo à produção de medicamentos de insulina e de dispositivos de administração impeça ainda o crescimento do mercado de medicamentos de insulina humana e de dispositivos de administração no período de tempo.

Além disso, o aumento da procura de análogos da HI proporcionará ainda mais oportunidades potenciais para o crescimento do mercado de medicamentos e dispositivos de administração de insulina humana nos próximos anos. No entanto, a ocorrência de regulamentos rigorosos para o lançamento de dispositivos médicos poderá desafiar ainda mais o crescimento do mercado de medicamentos e dispositivos de administração de insulina humana num futuro próximo.

This human insulin drugs and delivery devices market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on human insulin drugs and delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Europe Human Insulin Drugs and Delivery Devices Market Scope and Market Size

The human insulin drugs and delivery devices market is segmented on the basis of drugs, device, delivery devices, application, product, distribution channel and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications. 

On the basis of drugs, the human insulin drugs and delivery devices market is segmented into basal or long acting insulins, bolus or fast-acting insulins, traditional human insulins, combination insulins and biosimilar insulins. Basal or long acting insulins is further sub segmented into lantus, levemir, toujeo, tresiba and basaglar. Bolus or fast-acting insulins is further sub segmented into novorapid/novolog, humalog, apidra, fiasp and admelog. Traditional human insulins is further sub segmented into novolin/actrapid/insulatard, humulin and insuman. Combination insulins is further sub segmented into novomix, ryzodeg, xultophy and soliqua or suliqua. Biosimilar insulins is further sub segmented into insulin glargine biosimilars and human insulin biosimilars.

• On the basis of device, the human insulin drugs and delivery devices market is segmented into insulin pumps, insulin pens, insulin syringes, insulin jet injectors. Insulin pumps is further sub segmented into insulin pump devices, insulin pump reservoirs and insulin infusion sets. Insulin pens is further sub segmented into cartridges in reusable pens and disposable insulin pens.
• On the basis of delivery devices, the human insulin drugs and delivery devices market is segmented into syringes, pens, pen needles. Pens is further sub segmented into disposable pens and reusable pens. Pen needles is further sub segmented into standard pen needles and safety pen needles.
• On the basis of application, the human insulin drugs and delivery devices market is segmented into type II diabetes, type II diabetes.
• On the basis of product, the human insulin drugs and delivery devices market is segmented into HI drugs, HI delivery devices.
• On the basis of distribution channel, the human insulin drugs and delivery devices market is segmented into hospital pharmacy, retail pharmacy, online sales, diabetes clinics or centers and other.
• On the basis of end user, the human insulin drugs and delivery devices market is segmented into hospitals and clinics, homecare and specialty centers.

Europe Human Insulin Drugs and Delivery Devices Market Country Level Analysis

The human insulin drugs and delivery devices market is analysed and market size insights and trends are provided by country, drugs, device, delivery devices, application, product, distribution channel and end user as referenced above.      

The countries covered in the human insulin drugs and delivery devices market report are the Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.

Germany dominates the human insulin drugs and delivery devices market due to the increase in the incidence of diabetes among the country's population. Furthermore, growing number of patients with Type 1 and Type 2 diabetes will further boost the growth of the human insulin drugs and delivery devices market during the forecast period.

The country section of the human insulin drugs and delivery devices market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare infrastructure growth installed base and new technology penetration

The human insulin drugs and delivery devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for human insulin drugs and delivery devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the human insulin drugs and delivery devices market. The data is available for historic period 2010-2019.

Competitive Landscape and Europe Human Insulin Drugs and Delivery Devices Market Share Analysis

O panorama competitivo do mercado de medicamentos de insulina humana e dispositivos de administração fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença global, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa , lançamento de produto, largura e amplitude do produto, aplicação domínio. Os dados acima fornecidos estão apenas relacionados com o foco das empresas relacionado com o mercado de medicamentos de insulina humana e dispositivos de administração.

Os principais players abrangidos no relatório de mercado de medicamentos de insulina humana e dispositivos de administração são a Medtronic, BD, YPSOMED, ​​​​Insulet Corporation, Biocon, Lilly, Sanofi, Novo Nordisk A/S, Merck Sharp & Dohme Corp., F. Hoffmann-La Roche Ltd , GlaxoSmithKline plc e Pfizer Inc., entre outros players nacionais e globais. Os dados de quota de mercado estão disponíveis para a global, América do Norte, Europa, Ásia-Pacífico (APAC), Médio Oriente e África (MEA) e América do Sul separadamente. Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

SKU-1953